Search Result

Results for "

TGF-β Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TGF-beta/Smad (25) TGF-β Receptor (45) Akt (1) Anaplastic lymphoma kinase (ALK) (3) Androgen Receptor (1) Angiotensin Receptor (2) Apelin Receptor (APJ) (1) Apoptosis (9) Autophagy (2) Bacterial (1) Bcl-2 Family (1) Cadherin (1) Calcium Channel (7) CaSR (2) Collagen (1) COX (1) DNA/RNA Synthesis (7) EGFR (2) Endogenous Metabolite (1) ERK (2) FGFR (1) FLT3 (1) Formyl Peptide Receptor (FPR) (1) Integrin (2) Interleukin Related (2) Isotope-Labeled Compounds (1) JAK (1) Mixed Lineage Kinase (2) mRNA (5) mTOR (1) NF-κB (2) Organoid (6) p38 MAPK (2) Parasite (7) PARP (1) PD-1/PD-L1 (2) PDGFR (1) PI3K (4) Prostaglandin Receptor (2) PROTACs (1) Protease Activated Receptor (PAR) (2) Reactive Oxygen Species (ROS) (1) Reference Standards (7) RIP kinase (2) Sodium Channel (7) Src (1) STAT (1) Toll-like Receptor (TLR) (1) VD/VDR (1)
By Research Areas:	Cancer (55) Cardiovascular Disease (15) Endocrinology (5) Infection (12) Inflammation/Immunology (28) Metabolic Disease (9) Neurological Disease (4)
Oligonucleotides:	mRNA (5)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

SB-431542 Maximum Cited Publications 251 Publications Verification	Organoid TGF-β Receptor Apoptosis	Cancer
SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC₅₀ values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

LY2109761 55+ Cited Publications	TGF-β Receptor Autophagy	Cancer
LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with K_is of 38 nM and 300 nM, respectively.

Galunisertib 50+ Cited Publications LY2157299	TGF-β Receptor	Cancer
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

SB-431542 (Standard)	Apoptosis TGF-β Receptor Organoid Reference Standards	Cancer
SB-431542 (Standard) is the analytical standard of SB-431542. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC₅₀ values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

A 77-01 2 Publications Verification	TGF-β Receptor	Cancer
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC₅₀ of 25 nM .

GW788388 15+ Cited Publications	TGF-β Receptor	Cancer
GW788388 is a potent and selective inhibitor of ALK5 with IC₅₀ of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.

Pentabromophenol PBP	TGF-beta/Smad Apoptosis	Cancer
Pentabromophenol (PBP) is a brominated flame retardant (BFR) widely used in various consumer products to reduce the flammability of materials used in different utility items. Pentabromophenol can accelerate the degradation of transforming growth factor-β (TGF-β) receptors by promoting clathrin-mediated endocytosis, thereby inhibiting the *TGF-β* signaling pathway. Additionally, Pentabromophenol can also induce apoptosis in peripheral blood mononuclear cells (PBMCs) .

LY550410	TGF-β Receptor	Cancer
LY550410 is a small-molecule ATP-competitive inhibitor against *type I TGF-β* receptor kinase*, which contains heteroaryl rings for potent binding to the kinase-domain active site. LY550410 modulates TGF*-β signalling, thereby regulates gene expression and ultimately cell growth. LY550410 is promising for research of cancers .

Galunisertib monohydrate	TGF-β Receptor	Cancer
Galunisertib monohydrate is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

KRFK	TGF-β Receptor	Inflammation/Immunology
KRFK, a peptide derived from TSP-1, can activate *TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors* such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach .

KRFK TFA 3 Publications Verification	TGF-β Receptor	Inflammation/Immunology
KRFK TFA, a peptide derived from TSP-1, can activate *TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors* such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach .

Atractylodinol	Bacterial	Infection Cancer
Atractylodinol, an antimicrobial, is a PRRSV (porcine reproductive and respiratory syndrome virus) inhibitor. Atractylodinol inhibits TGF-β receptor I recycling by binding to vimentin (K_D of 454 nM) and inducing the formation of filamentous aggregates .

Galunisertib (Standard)	TGF-β Receptor	Cancer
Galunisertib (Standard) is the analytical standard of Galunisertib. This product is intended for research and analytical applications. Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.

LY2109761 (Standard)	TGF-β Receptor Autophagy	Cancer
LY2109761 (Standard) is the analytical standard of LY2109761. This product is intended for research and analytical applications. LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively.

(+)-ITD-1	TGF-beta/Smad TGF-β Receptor	Cardiovascular Disease
(+)-ITD-1 is an inhibitor for *TGF-β, that inhibits the TGF-β2 with an IC₅₀* of 0.46 μM. (+)-ITD-1 promotes the degradation of TGF-b type II receptor (TGFBR2) and the differentiation of cardiomyocyte, and inhibits the mesoderm formation in the early differentiation stage of mouse embryonic stem cells (mESCs) .

SB-505124 20+ Cited Publications	TGF-β Receptor	Cancer
SB-505124 is a selective inhibitor of **TGF-β Receptor type I receptors (ALK4, ALK5, ALK7), with IC₅₀**s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.

Elritercept KER-050	TGF-beta/Smad	Inflammation/Immunology
Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .

Cibotercept KER-012	TGF-beta/Smad	Inflammation/Immunology
Cibotercept (KER-012) is a novel, modified, investigational activin receptor type IIB (ActRIIB) ligand trap designed to target select TGF-β ligands, including activins A and B, GDFs 8 and 11, to rebalance the defective activin receptor type II signaling observed in PAH .

A 83-01 sodium 95+ Cited Publications	Organoid TGF-β Receptor	Cancer
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

LY3200882 10+ Cited Publications	TGF-β Receptor	Inflammation/Immunology Cancer
LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC₅₀ of 38.2 nM. LY3200882 inhibits various pro-tumorigenic activities and is also used as an immune modulatory agent .

A 83-01 95+ Cited Publications	Organoid TGF-β Receptor	Cancer
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

TQB-2858	PD-1/PD-L1	Cancer
TQB-2858 is a bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of **TGF-β receptor*. TQB-2858 has a high affinity for PD-L1, TGF-β1, and TGF*-β3 and exhibited high PD-L1 target occupancy. TQB-2858 can be used for the study of osteosarcoma and alveolar soft part sarcoma (ASPS) .

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

SB-431542	TGF-β Receptor	Neurological Disease Cancer
SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling .

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase ALK5 inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

ALK5-IN-7	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-7 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-7 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 4) .

ALK5-IN-6	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-6 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-6 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 1) .

SB-505124 hydrochloride (Standard)	TGF-β Receptor	Cancer
SB-505124 (hydrochloride) (Standard) is the analytical standard of SB-505124 (hydrochloride). This product is intended for research and analytical applications. SB-505124 hydrochloride is a selective inhibitor of TGF-β Receptor type I receptor (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.

SB-505124 (Standard)	TGF-β Receptor	Cancer
SB-505124 (Standard) is the analytical standard of SB-505124. This product is intended for research and analytical applications. SB-505124 is a selective inhibitor of TGF-β Receptor type I receptors (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.

Human TGFBR1 mRNA	mRNA	Cancer
Human TGFBR1 mRNA encodes the human transforming growth factor beta receptor 1 (TGFBR1) protein, a serine/threonine protein kinase. TGFBR1 can form a heteromeric complex with type II TGF-beta receptors when bound to TGF-beta, transducing the TGF-beta signal from the cell surface to the cytoplasm.

A 83-01 (Standard)	Reference Standards TGF-β Receptor	Cancer
A 83-01 (Standard) is the analytical standard of A 83-01 (HY-10432). This product is intended for research and analytical applications. A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

Klotho-derived peptide 1 hydrochloride KP1 (human) hydrochloride	TGF-beta/Smad p38 MAPK	Inflammation/Immunology
Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .

Klotho-derived peptide 1 KP1 (human)	TGF-beta/Smad p38 MAPK	Inflammation/Immunology
Klotho-derived peptide 1 (KP1 human) blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cancer
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

TGFβRII-IN-3	TGF-β Receptor TGF-beta/Smad	Cancer
TGFβRII-IN-3 (Compound 2r) is a selective inhibitor of the TGFβ type II receptor (TGFβ RII) (IC₅₀ = 4.1 μM). TGFβRII-IN-3 inhibits TGFβ signaling by promoting the proteolytic degradation of TGFβ RII. TGFβRII-IN-3 can block endothelial-to-mesenchymal transition and cell migration. TGFβRII-IN-3 can be used in cancer research .

RepSox 20+ Cited Publications E-616452; SJN 2511	Organoid TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

ITD-1 5 Publications Verification	TGF-β Receptor	Cardiovascular Disease
ITD-1 is the first selective **TGFβ receptor inhibitor with an IC₅₀** of 460 nM.

PD-161570	FGFR PDGFR EGFR Src TGF-β Receptor	Cardiovascular Disease Cancer
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC₅₀ of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC₅₀ values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC₅₀s of 450 nM and 622 nM, respectively . PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor .

RepSox (Standard)	Organoid TGF-β Receptor	Metabolic Disease
RepSox (Standard) is the analytical standard of RepSox. This product is intended for research and analytical applications. RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

Human TGFBR3 mRNA	mRNA	Inflammation/Immunology
Human TGFBR3 mRNA encodes the human transforming growth factor beta receptor 3 (TGFBR3) protein, a transforming growth factor (TGF)-beta type III receptor. TGFBR3 is a membrane proteoglycan that often functions as a co-receptor with other TGF-beta receptor superfamily members. Ectodomain shedding produces soluble TGFBR3, which may inhibit TGFB signaling. Decreased expression of this receptor has been observed in various cancers.

Halofuginone 15+ Cited Publications RU-19110	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

Halofuginone lactate 15+ Cited Publications RU-19110 lactate	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM . Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity . Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

BIBF0775	TGF-β Receptor	Cancer
BIBF0775 is a potent and selective *transforming growth factor β (TGFβ) type I receptor* (Alk5) inhibitor with an IC₅₀** of 34 nM.

Halofuginone hydrochloride 15+ Cited Publications RU-19110 hydrochloride	Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

Isosaponarin	TGF-β Receptor Collagen	Infection Metabolic Disease Inflammation/Immunology Cancer
Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin is a P4HA2 enzymatic agonist. Isosaponarin increases collagen synthesis via up-regulated TGF-β type II receptor (TβR-II) and prolyl 4-hydroxylase (P4H) proteins production, promoting skin health and wound healing. Isosaponarin-rich plants exhibit strong antimicrobial, antioxidant, anti-hyaluronidase, antiplatelet, anti-atopic dermatitis, and anti-tumor effects .

Halofuginone hydrobromide 15+ Cited Publications RU-19110 hydrobromide	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

Cat. No.	Product Name

HY-L018

TGF-beta/Smad Compound Library

349 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 349 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

HY-L074

Anti-Breast Cancer Compound Library

2,713 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,713 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-10431G

SB-431542 (GMP)	Fluorescent Dye
SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling .

Cat. No.	Product Name	Type

HY-10431G

SB-431542 (GMP)	Biochemical Assay Reagents
SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling .

HY-120973

Butaprost free acid	Biochemical Assay Reagents
Butaprost free acid is a selective *prostaglandin E receptor* (EP2) agonist with an EC₅₀ of 33 nM and a K_i** of 2.4 μM for murine EP2 receptor. Butaprost free acid is less activity against murine EP1, EP3 and EP4 receptors. Butaprost free acid attenuates fibrosis by hampering *TGF-β/Smad2* signalling .

Cat. No.	Product Name	Target	Research Area

HY-P3970A

KRFK TFA 3 Publications Verification	TGF-β Receptor	Inflammation/Immunology
KRFK TFA, a peptide derived from TSP-1, can activate *TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors* such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach .

HY-P10414A

Klotho-derived peptide 1 hydrochloride KP1 (human) hydrochloride	TGF-beta/Smad p38 MAPK	Inflammation/Immunology
Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .

HY-P2294A

pm26TGF-β1 peptide TFA 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the **TGF-β1 receptor*. pm26TGF*-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .

HY-P0118B

Disitertide diammonium Maximum Cited Publications 15 Publications Verification P144 diammonium	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer .

HY-P2196A

ELA-32(human) TFA 1 Publications Verification	Apelin Receptor (APJ)	Cancer
ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC₅₀=0.27 nM; K_d=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.

HY-P3970

KRFK	TGF-β Receptor	Inflammation/Immunology
KRFK, a peptide derived from TSP-1, can activate *TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors* such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach .

HY-P10414

Klotho-derived peptide 1 KP1 (human)	TGF-beta/Smad p38 MAPK	Inflammation/Immunology
Klotho-derived peptide 1 (KP1 human) blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .

HY-P2294

pm26TGF-β1 peptide	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide shows high affinity for the **TGF-β1 receptor*. pm26TGF*-β1 peptide displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .

HY-P0118

Disitertide P144	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer .

HY-P0118A

Disitertide TFA P144 TFA	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer .

HY-P3136A

TRV055 hydrochloride TRV120055 hydrochloride	Angiotensin Receptor	Cardiovascular Disease
TRV055 (TRV120055) (hydrochloride) is a G protein-biased agonist of angiotensin II type 1 receptors (AT1Rs). TRV120055 induces fibroblast proliferation, overexpression of collagen I and α-SMA, and stress fibre formation in human cardiac fibroblasts. TRV055 activates AT1 receptor/Gαq-mediated signaling pathways, upregulates *TGF-β1* and p-ERK1/2. TRV055 induces collagen secretion in adult rat myofibroblasts at a level comparable to Ang II. TRV055 can be used to study the role of G protein-biased signaling of AT1Rs in regulating fibrotic responses ^[1]

HY-P3136

TRV055 TRV120055	Angiotensin Receptor ERK	Cardiovascular Disease
TRV055 (TRV120055) is a G protein-biased agonist of angiotensin II type 1 receptors (AT1Rs). TRV120055 induces fibroblast proliferation, overexpression of collagen I and α-SMA, and stress fibre formation in human cardiac fibroblasts. TRV055 activates AT1 receptor/Gαq-mediated signaling pathways, upregulates *TGF-β1* and p-ERK1/2. TRV055 induces collagen secretion in adult rat myofibroblasts at a level comparable to Ang II. TRV055 can be used to study the role of G protein-biased signaling of AT1Rs in regulating fibrotic responses ^[1]

Cat. No.	Product Name	Target	Research Area

HY-P990733

Cibotercept KER-012	TGF-beta/Smad	Inflammation/Immunology
Cibotercept (KER-012) is a novel, modified, investigational activin receptor type IIB (ActRIIB) ligand trap designed to target select TGF-β ligands, including activins A and B, GDFs 8 and 11, to rebalance the defective activin receptor type II signaling observed in PAH .

HY-P99590A

Sotatercept (mIgG2a) RAP-011	TGF-β Receptor TGF-beta/Smad	Cardiovascular Disease Metabolic Disease
Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) (HY-P99590), is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic) .

HY-P990720

Elritercept KER-050	TGF-beta/Smad	Inflammation/Immunology
Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .

HY-P991084

TQB-2858	PD-1/PD-L1	Cancer
TQB-2858 is a bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of **TGF-β receptor*. TQB-2858 has a high affinity for PD-L1, TGF-β1, and TGF*-β3 and exhibited high PD-L1 target occupancy. TQB-2858 can be used for the study of osteosarcoma and alveolar soft part sarcoma (ASPS) .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

Species:	Human (11) Rhesus Macaque (1) Mouse (4) Rat (1)
Tag:	His (10) GST (1) Fc (8)
Source:	HEK293 (14) Sf9 insect cells (1) Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P7426

	TGFBR2/TGF-beta RII Protein, Human (HEK293, Fc) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Human	HEK293
	TGF-beta receptor 2 Protein, Human (HEK293, Fc), a fragment of transforming growth factor-beta receptor type 2 (TβRII), consists of amino acid of Thr23-Asp159 with an Fc tag at the C-terminus.

HY-P7427

	TGFBR2/TGF-beta RII Protein, Mouse (HEK293, Fc) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Mouse	HEK293
	TGFBR2/TGF-beta RII Protein, Mouse (HEK293, Fc), a fragment of transforming growth factor-beta receptor type 2 (TβRII), with a 6His tag at the C-terminus.

HY-P7428

	TGFBR2/TGF-beta RII Protein, Mouse (HEK293, His) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Mouse	HEK293
	TGFBR2/TGF-beta RII Protein, Mouse (HEK293, His), His consists of N-terminal ectodomain and C-terminal protein kinase domain with his tag.TGF-beta receptor type-2 is the ligand-binding receptor for all members of the TGF-β family.

HY-P73428

	TGFBR2/TGF-beta RII Protein, Human (sf9, His) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Human	Sf9 insect cells
	The TGFBR2/TGF-β RII protein cooperates with TGFBR1 to form dedicated receptors for TGFB1, TGFB2, and TGFB3. It serves as a signal transducer that coordinates diverse physiological and pathological processes, including cell cycle regulation, mesenchymal cell dynamics, wound healing, matrix production, immunosuppression, and carcinogenesis. TGFBR2/TGF-beta RII Protein, Human (sf9, His) is the recombinant human-derived TGFBR2/TGF-beta RII protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P73430

	TGFBR2/TGF-beta RII Protein, Rat (HEK293, Fc) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Rat	HEK293
	TGFBR2 is a transmembrane kinase that forms the TGF-β receptor complex with TGFBR1 and regulates various processes. Upon binding to cytokines, this complex activates TGFBR2, initiating SMAD-dependent signaling through phosphorylation of TGFBR1, SMAD2, and SMAD4. TGFBR2/TGF-beta RII Protein, Rat (HEK293, Fc) is the recombinant rat-derived TGFBR2/TGF-beta RII protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77229

	TGFBR2/TGF-beta RII Protein, Rhesus Macaque (HEK293, Fc) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Rhesus Macaque	HEK293
	TGFBR2/TGF-beta RII Protein collaborates with TGFBR1 to form a dedicated receptor for TGFB1, TGFB2, and TGFB3. It serves as a signal transducer, orchestrating diverse physiological and pathological processes, including cell cycle regulation, mesenchymal cell dynamics, wound healing, matrix production, immunosuppression, and carcinogenesis. Upon cytokine binding, the receptor complex activates TGFBR1 through TGFBR2 phosphorylation, initiating the canonical SMAD-dependent TGF-beta signaling cascade. Additionally, TGFBR2 participates in non-canonical, SMAD-independent pathways. TGFBR2/TGF-beta RII Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived TGFBR2/TGF-beta RII protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P72453

	TGFBR1/ALK-5 Protein, Human (HEK293, Fc) TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5	Human	HEK293
	TGFBR1/ALK-5 proteins cooperate with TGFBR2 to form dedicated receptors for TGFB1, TGFB2, and TGFB3, transmitting signals and coordinating different physiological and pathological processes. It induces cell cycle arrest, modulates mesenchymal cell dynamics, contributes to wound healing, and affects immunosuppression and carcinogenesis. TGFBR1/ALK-5 Protein, Human (HEK293, Fc) is the recombinant human-derived TGFBR1/ALK-5 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P72454

	TGFBR1/ALK-5 Protein, Mouse (HEK293, Fc) 1 Publications Verification TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5	Mouse	HEK293
	TGFBR1 is a transmembrane kinase that cooperates with TGFBR2 to form the TGF-β receptor complex.This complex is activated by cytokines and regulates a variety of processes, including cell cycle arrest, mesenchymal cell control, wound healing, and carcinogenesis.TGFBR1/ALK-5 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived TGFBR1/ALK-5 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74521

	TGFBR3/TGF-beta RIII Protein, Human (sf9, His) TGFBR3; TGF-bRIII; TGFR-3; Transforming growth factor beta Receptor III; Betaglycan	Human	Sf9 insect cells
	TGFBR3/TGF-beta RIII Protein is pivotal, binding to TGF-beta, indicating a potential role in capturing and presenting TGF-beta to signaling receptors. In gonadotrope cells, it acts as an inhibin A coreceptor, regulating FSH levels and impacting female fertility. Its interaction with DYNLT4 emphasizes diverse functional associations in cellular processes, suggesting a multifaceted role for TGFBR3 in cellular regulation and fertility control. TGFBR3/TGF-beta RIII Protein, Human (sf9, His) is the recombinant human-derived TGFBR3/TGF-beta RIII protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P704919

	TGFBR2/TGF-beta RII Protein, Human (HEK293, His) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Human	HEK293

HY-P74522

	TGFBR1/ALK-5 Protein, Human (sf9, His-GST) TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5	Human	Sf9 insect cells
	TGFBR1/ALK-5 proteins cooperate with TGFBR2 to form dedicated receptors for TGFB1, TGFB2, and TGFB3, transmitting signals and coordinating different physiological and pathological processes. It induces cell cycle arrest, modulates mesenchymal cell dynamics, contributes to wound healing, and affects immunosuppression and carcinogenesis. TGFBR1/ALK-5 Protein, Human (sf9, His-GST) is the recombinant human-derived TGFBR1/ALK-5 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P74523

	TGFBR1/ALK-5 Protein, Human (HEK293, His-Fc) TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5	Human	HEK293
	TGFBR1/ALK-5 proteins cooperate with TGFBR2 to form dedicated receptors for TGFB1, TGFB2, and TGFB3, transmitting signals and coordinating different physiological and pathological processes. It induces cell cycle arrest, modulates mesenchymal cell dynamics, contributes to wound healing, and affects immunosuppression and carcinogenesis. TGFBR1/ALK-5 Protein, Human (HEK293, His-Fc) is the recombinant human-derived TGFBR1/ALK-5 protein, expressed by HEK293 , with C-hFc, C-His labeled tag.

HY-P704918

	TGFBR1/ALK-5 Protein, Human (HEK293, Llama Fc) TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5	Human	HEK293

HY-P704920

	TGFBR3/TGF-beta RIII Protein, Human (HEK293, His) TGFBR3; TGF-bRIII; TGFR-3; Transforming growth factor beta Receptor III; Betaglycan	Human	HEK293

HY-P72452

	TGFBR3/TGF-beta RIII Protein, Mouse (763a.a, HEK293, His) TGFBR3; TGF-bRIII; TGFR-3; Transforming growth factor beta Receptor III	Mouse	HEK293
	TGFBR3/TGF-beta RIII Protein is pivotal, binding to TGF-beta, indicating a potential role in capturing and presenting TGF-beta to signaling receptors.In gonadotrope cells, it acts as an inhibin A coreceptor, regulating FSH levels and impacting female fertility.Its interaction with DYNLT4 emphasizes diverse functional associations in cellular processes, suggesting a multifaceted role for TGFBR3 in cellular regulation and fertility control.TGFBR3/TGF-beta RIII Protein, Mouse (HEK293, His) is the recombinant mouse-derived TGFBR3/TGF-beta RIII protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70384

	GFRA1/GDNFR-alpha-1 Protein, Human (HEK293, His) rHuGDNF family Receptor alpha-1/GFRA1, His; GFRα1; GDNF Family Receptor Alpha-1; GDNF Receptor Alpha-1; GDNFR-Alpha-1; GFR-Alpha-1; RET Ligand 1; TGF-Beta-Related Neurotrophic Factor Receptor 1; GFRA1; GDNFRA; RETL1; TRNR1	Human	HEK293
	The GFRA1/GDNFR-alpha-1 Protein serves as a receptor for GDNF, facilitating GDNF-induced autophosphorylation and activation of the RET receptor. In a complex, two molecules of GDNFR-alpha-1 are believed to associate with the disulfide-linked GDNF dimer and two molecules of RET. It interacts with RET and SORL1, either alone or in a complex with GDNF, leading to GFRA1 internalization without degradation. GFRA1/GDNFR-alpha-1 Protein, Human (HEK293, His) is the recombinant human-derived GFRA1/GDNFR-alpha-1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70192

	GFRA2/GDNFR-alpha-2 Protein, Human (HEK293, His) rHuGDNF family Receptor alpha-2/GFRA2, His ; GDNF Family Receptor Alpha-2; GDNF Receptor Alpha-2; GDNFR-Alpha-2; GFR-Alpha-2; GDNF Receptor Beta; GDNFR-Beta; Neurturin Receptor Alpha; NRTNR-Alpha; NTNR-Alpha; RET Ligand 2; TGF-Beta-Related Neurotrophic Factor Receptor 2; GFRA2; GDNFRB; RETL2; TRNR2	Human	HEK293
	GFRA2, also known as GDNFR-α-2, acts as a receptor for neurotrophic factor (NRTN) and promotes NRTN-induced autophosphorylation and RET receptor activation. In addition to neurotrophic factor signaling, GFRA2 can also mediate GDNF signaling through the RET tyrosine kinase. GFRA2/GDNFR-alpha-2 Protein, Human (HEK293, His) is the recombinant human-derived GFRA2/GDNFR-alpha-2 protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81131

	TGF beta Receptor II Antibody TGF-beta Receptor type-2; TGF beta R2; TGFBR2; AAT 3; AAT3; FAA 3; FAA3; HNPCC6; MFS 2; MFS2; RIIC; TAAD 2; TAAD2; TbetaR II; TGF beta Receptor type 2; TGF beta Receptor type II; TGF beta type II Receptor; TGFB R2; TGFbeta RII; TGFBR 2; TGFR 2; TGFR2; Transforming growth factor beta Receptor II; Transforming growth factor beta Receptor type II. TGF-βRⅡ; TGFβRⅡ; TGF βRⅡ; TGFβ RⅡ.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse, Rat
	TGF beta Receptor II Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to TGF beta Receptor II.

HY-P85977

	TGF β Receptor I Antibody (YA5669)	IHC-P, ICC/IF, ELISA	Human, Mouse, Rat, Bovin
	TGF β Receptor I Antibody (YA5669) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to TGF β Receptor I.

HY-P86481

	TGF beta Receptor II Antibody (YA6173) TGFBR2; TGF-beta Receptor type-2; TGFR-2; TGF-beta type II Receptor; Transforming growth factor-beta Receptor type II; TGF-beta Receptor type II; TbetaR-II	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	TGF beta Receptor II Antibody (YA6173) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TGF β Receptor II. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.

HY-P85969

	TGF beta Receptor II Antibody (YA5661)	IHC-P, WB, ICC/IF, ELISA	Human
	TGF beta Receptor II Antibody (YA5661) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TGF beta Receptor II.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-174531

Human TGFBR1 mRNA		mRNA
Human TGFBR1 mRNA encodes the human transforming growth factor beta receptor 1 (TGFBR1) protein, a serine/threonine protein kinase. TGFBR1 can form a heteromeric complex with type II TGF-beta receptors when bound to TGF-beta, transducing the TGF-beta signal from the cell surface to the cytoplasm.

HY-174529

Human TGFBR3 mRNA		mRNA
Human TGFBR3 mRNA encodes the human transforming growth factor beta receptor 3 (TGFBR3) protein, a transforming growth factor (TGF)-beta type III receptor. TGFBR3 is a membrane proteoglycan that often functions as a co-receptor with other TGF-beta receptor superfamily members. Ectodomain shedding produces soluble TGFBR3, which may inhibit TGFB signaling. Decreased expression of this receptor has been observed in various cancers.

HY-174530

Human TGFBR2 mRNA		mRNA
Human TGFBR2 mRNA encodes the human transforming growth factor beta receptor 2 (TGFBR2) protein, a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with TGF-beta receptor type-1, and binds TGF-beta. TGFBR2/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of genes related to cell proliferation, cell cycle arrest, wound healing, immunosuppression, and tumorigenesis.

HY-174774

Human BMPR1B mRNA		mRNA
Human BMPR1B mRNA encodes the human bone morphogenetic protein receptor type 1B (BMPR1B) protein, a family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis.

HY-174781

Human ACVRL1 mRNA		mRNA
Human ACVRL1 mRNA encodes the human activin A receptor like type 1 (ACVRL1) protein. ACVRL1 is a type I cell-surface receptor for the TGF-beta superfamily ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks